Switching From Tobramycin Inhalation Treatment to Tobramycin Inhaler Treatment: The Effect on CF Patients' Adherence and Quality of Life
- Conditions
- Alteration in Quality of Life of CF Patients, Following Change of Treatment From Antibiotic Inhalation to Antibiotic Inhaler
- Registration Number
- NCT01749644
- Lead Sponsor
- Sheba Medical Center
- Brief Summary
Pseudomonas is a common and virulent respiratory bacteria in patients with Cystic Fibrosis (CF). With time, the infection with Pseudomonas becomes chronic and very difficult to eradicate. The standard treatment of chronic Pseudomonas infection is inhaled Tobramycin which is given every other month.. Inhalation of Tobramycin was proven as an effective treatment that improves the respiratory function and reduces the concentration of bacteria in the sputum. However, inhaled treatment lasts between 15 to 30 minutes twice a day and therefore adherence is a major problem. The effect of switching from inhalation treatment to inhaler treatment on patient's adherence and quality of life has not been studied.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
- Age 6 years and above, Chronic Pseudomonas infection
- Younger than 6 years; No chronic PSeudomonas infection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in quality of life 1 year
- Secondary Outcome Measures
Name Time Method Difference in exacerbation events 1 year To be measured by:
Worsening of CF symptoms such as coughing, sputum, deterioration in FEV1, all of which require hospitalization
Trial Locations
- Locations (1)
Safra Children's Hospital, Sheba Medical Center
🇮🇱Ramat Gan, Israel